THE NEBRASKA MEDICAL CENTER
- Type
- Teaching hospital
- Where
- OMAHA, NE
- Medicare CCN
- 280013
- Received
- $971,934 in 312 records, 2019 ($224,531 general, $747,402 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: THE NEBRASKA MEDICAL CENTER Fuzzy (name and state)
- Business registration: THE NEBRASKA MEDICAL CENTER CORPORATION Fuzzy (name and state)
- Plan sponsor: THE NEBRASKA MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: NEBRASKA MEDICAL CENTER, THE Fuzzy (name and state)
- Federal award recipient: NEBRASKA MEDICAL CENTER, THE Fuzzy (name and state)
- Nonprofit: THE NEBRASKA MEDICAL CENTER Fuzzy (name and state)
- Trademark owner: The Nebraska Medical Center Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 100 | $224,531 |
| 2019 | Research payment | 212 | $747,402 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 212 | $747,402 |
| Grant | 12 | $153,093 |
| Consulting Fee | 5 | $34,419 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 74 | $29,650 |
| Gift | 2 | $4,694 |
| Space rental or facility fees (teaching hospital only) | 4 | $2,300 |
| Education | 2 | $225 |
| Food and Beverage | 1 | $149 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | Masimo Corporation | $143 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2019 | |
| 2019-12-31 | Masimo Corporation | $82 | Education | In-kind items and services | EMMA and ISA Device, Devices | 2019 | |
| 2019-12-31 | Zimmer Biomet Holdings, Inc. | $25 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2019 | |
| 2019-12-30 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-12-26 | Philips North America LLC | $6,092 | Consulting Fee | Cash or cash equivalent | HealthTec Device, Cardiology/Vascular Diseases | 2019 | |
| 2019-12-26 | Merck Sharp & Dohme LLC | $607 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-12-26 | Merck Sharp & Dohme LLC | $45 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-12-23 | Philips North America LLC | $12,962 | Consulting Fee | Cash or cash equivalent | HealthTec Device, Cardiology/Vascular Diseases | 2019 | |
| 2019-12-23 | Philips North America LLC | $6,919 | Consulting Fee | Cash or cash equivalent | HealthTec Device, Cardiology/Vascular Diseases | 2019 | |
| 2019-12-23 | Philips North America LLC | $6,092 | Consulting Fee | Cash or cash equivalent | HealthTec Device, Cardiology/Vascular Diseases | 2019 | |
| 2019-12-19 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-12-19 | Merck Sharp & Dohme LLC | $166 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adju | 2019 |
| 2019-12-19 | Merck Sharp & Dohme LLC | $91 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-12-19 | Merck Sharp & Dohme LLC | $58 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-12-13 | Merck Sharp & Dohme LLC | $303 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-12-11 | PFIZER INC. | $57,783 | Research payment | In-kind items and services | BESPONSA Biological, ONCOLOGY | A PHASE 4 OPENLABEL RANDOMIZED STUDY OF TWO INOTUZUMAB OZOGAMICIN DOSE LEVELS IN ADULT PATIENTS WITH RELAPSED OR REFRACT | 2019 |
| 2019-12-11 | Insulet Corporation | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (17 payments) | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2019 | |
| 2019-12-10 | BioFire Diagnostics, LLC | $4,060 | Research payment | Cash or cash equivalent | FilmArray System Device, Clinical Diagnostics | FilmArray BJI Pivotal Study | 2019 |
| 2019-12-05 | Insulet Corporation | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (17 payments) | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2019 | |
| 2019-12-04 | C. R. Bard, Inc. & Subsidiaries | $400 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-12-04 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-12-04 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-12-03 | BioFire Diagnostics, LLC | $4,500 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray BJI Pivotal Study | 2019 |
| 2019-12-03 | Merck Sharp & Dohme LLC | $91 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-11-29 | Merck Sharp & Dohme LLC | $16,239 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy ,- Pembrolizumab MK-3475 as Neoadjuvant,Adj | 2019 |
| 2019-11-25 | Insulet Corporation | $625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (17 payments) | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2019 | |
| 2019-11-22 | Merck Sharp & Dohme LLC | $27,431 | Research payment | Cash or cash equivalent | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-11-22 | Merck Sharp & Dohme LLC | $291 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-11-21 | Merck Sharp & Dohme LLC | $455 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-11-21 | Merck Sharp & Dohme LLC | $137 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-11-21 | BioFire Diagnostics, LLC | $103 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray BJI Pivotal Study | 2019 |
| 2019-11-21 | Merck Sharp & Dohme LLC | $87 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-11-21 | Merck Sharp & Dohme LLC | $46 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adju | 2019 |
| 2019-11-20 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-11-15 | Artivion, Inc. | $4,300 | Research payment | Cash or cash equivalent | PhotoFix Device, Cardiology and Vascular Diseases | Post-market, prospective evaluation of PHOTO-oxidized decellularized bovine pericardium used as a patch in Vascular repa | 2019 |
| 2019-11-12 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-11-08 | W. L. Gore & Associates, Inc. | $5,040 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Gore Research and Development | 2019 |
| 2019-11-08 | APPLIED MEDICAL TECHNOLOGY INC | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | Bridle Device, Enteral | 2019 | |
| 2019-11-04 | ZOLL Medical Corporation | $750 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Device, DEFIBRILLATOR | 2019 | |
| 2019-11-04 | Merck Sharp & Dohme LLC | $455 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-11-04 | Merck Sharp & Dohme LLC | $45 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-10-31 | Insulet Corporation | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (17 payments) | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2019 | |
| 2019-10-30 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-10-30 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-10-30 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-10-28 | Merck Sharp & Dohme LLC | $413 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adju | 2019 |
| 2019-10-18 | Mallinckrodt Enterprises LLC | $1,285 | Research payment | Cash or cash equivalent | ACTHAR Biological, AUTOIMMUNE AND RARE DISEASE | A DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF H.P. ACTHAR GEL IN THE MANAGEMENT OF AMYOTROPHIC LATERAL SCLEROSIS | 2019 |
| 2019-10-17 | Merck Sharp & Dohme LLC | $455 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-10-17 | Merck Sharp & Dohme LLC | $91 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-10-16 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-10-16 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-10-16 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-10-16 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-10-10 | Osteomed LLC | $5,250 | Grant | Cash or cash equivalent | Device, NEURO-OTHER | 2019 | |
| 2019-10-10 | Osteomed LLC | $5,000 | Grant | Cash or cash equivalent | Device, CMF-OTHER | 2019 | |
| 2019-10-10 | Osteomed LLC | $5,000 | Grant | Cash or cash equivalent | Device, CMF-OTHER | 2019 | |
| 2019-10-09 | TransMedics, Inc. | $20,035 | Research payment | Cash or cash equivalent | Organ Care System Device, Device | PROTECT LIVER | 2019 |
| 2019-10-09 | Tandem Diabetes Care, Inc. | $300 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-10-09 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-10-09 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-10-09 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-10-09 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-10-08 | Merck Sharp & Dohme LLC | $696 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-10-08 | Merck Sharp & Dohme LLC | $117 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-10-08 | Merck Sharp & Dohme LLC | $103 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-10-08 | Merck Sharp & Dohme LLC | $78 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-10-08 | Merck Sharp & Dohme LLC | $60 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-10-08 | Merck Sharp & Dohme LLC | $41 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-10-08 | Merck Sharp & Dohme LLC | $12 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-10-08 | Merck Sharp & Dohme LLC | $6 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-10-08 | Merck Sharp & Dohme LLC | $3 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-10-08 | Merck Sharp & Dohme LLC | $1 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-10-08 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-10-08 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-10-08 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-10-04 | Mallinckrodt Enterprises LLC | $3,486 | Research payment | Cash or cash equivalent | ACTHAR Biological, AUTOIMMUNE AND RARE DISEASE | A DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF H.P. ACTHAR GEL IN THE MANAGEMENT OF AMYOTROPHIC LATERAL SCLEROSIS | 2019 |
| 2019-10-02 | Merck Sharp & Dohme LLC | $21,775 | Research payment | Cash or cash equivalent | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-10-02 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-10-02 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-10-02 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-10-02 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-10-01 | BioFire Diagnostics, LLC | $4,500 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray BJI Pivotal Study | 2019 |
| 2019-10-01 | BioFire Diagnostics, LLC | $4,500 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray BJI Pivotal Study | 2019 |
| 2019-10-01 | Insulet Corporation | $225 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (17 payments) | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2019 | |
| 2019-09-27 | Merck Sharp & Dohme LLC | $776 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-09-27 | Merck Sharp & Dohme LLC | $303 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-09-27 | Merck Sharp & Dohme LLC | $45 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-09-25 | Insulet Corporation | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (17 payments) | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2019 | |
| 2019-09-24 | Mallinckrodt Enterprises LLC | $7,538 | Research payment | Cash or cash equivalent | ACTHAR Biological, AUTOIMMUNE AND RARE DISEASE | A DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF H.P. ACTHAR GEL IN THE MANAGEMENT OF AMYOTROPHIC LATERAL SCLEROSIS | 2019 |
| 2019-09-18 | Surmodics, Inc. | $945 | Research payment | Cash or cash equivalent | SurVeil Device, Drug-Coated Balloon | TRANSCEND | 2019 |
| 2019-09-18 | Surmodics, Inc. | $945 | Research payment | Cash or cash equivalent | SurVeil Device, Drug-Coated Balloon | TRANSCEND | 2019 |
| 2019-09-18 | Surmodics, Inc. | $945 | Research payment | Cash or cash equivalent | SurVeil Device, Drug-Coated Balloon | TRANSCEND | 2019 |
| 2019-09-18 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-09-13 | TransMedics, Inc. | $3,591 | Research payment | Cash or cash equivalent | Organ Care System Device, Device | EXPAND LUNG II | 2019 |
| 2019-09-12 | Merck Sharp & Dohme LLC | $759 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-09-11 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-09-10 | Merck Sharp & Dohme LLC | $348 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-09-10 | Merck Sharp & Dohme LLC | $173 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-09-10 | Merck Sharp & Dohme LLC | $140 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-09-10 | Merck Sharp & Dohme LLC | $124 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-09-10 | Merck Sharp & Dohme LLC | $118 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-09-10 | Merck Sharp & Dohme LLC | $103 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-09-10 | Merck Sharp & Dohme LLC | $78 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-09-10 | Merck Sharp & Dohme LLC | $72 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-09-10 | Merck Sharp & Dohme LLC | $60 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-09-10 | Merck Sharp & Dohme LLC | $18 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-09-10 | Merck Sharp & Dohme LLC | $10 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-09-10 | Merck Sharp & Dohme LLC | $8 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-09-10 | Merck Sharp & Dohme LLC | $8 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-09-10 | Merck Sharp & Dohme LLC | $3 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-09-10 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-09-10 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-09-10 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-09-05 | Insulet Corporation | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (17 payments) | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2019 | |
| 2019-08-29 | Insulet Corporation | $625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (17 payments) | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2019 | |
| 2019-08-28 | Merck Sharp & Dohme LLC | $6,951 | Research payment | Cash or cash equivalent | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-08-26 | BioFire Diagnostics, LLC | $9,111 | Research payment | In-kind items and services | FilmArray System Device, Clinical Diagnostics | FilmArray BJI Pivotal Study | 2019 |
| 2019-08-15 | Tandem Diabetes Care, Inc. | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-08-15 | Merck Sharp & Dohme LLC | $303 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-08-15 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-08-14 | Shionogi Inc | $2,352 | Consulting Fee | Cash or cash equivalent | Fetroja Drug, Infections and Infectious Diseases | 2019 | |
| 2019-08-14 | Insulet Corporation | $625 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (17 payments) | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2019 | |
| 2019-08-11 | Artivion, Inc. | $6,595 | Research payment | Cash or cash equivalent | PhotoFix Device, Cardiology and Vascular Diseases | Post-market, prospective evaluation of PHOTO-oxidized decellularized bovine pericardium used as a patch in Vascular repa | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $316 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $158 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $140 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $103 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $103 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $103 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $13 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $3 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $1 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $1 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-08-08 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-08-02 | Linvatec Corporation | $2,593 | Grant | In-kind items and services | AIRSEAL Device, GENERAL SURGERY | 2019 | |
| 2019-07-26 | Merck Sharp & Dohme LLC | $8,339 | Research payment | Cash or cash equivalent | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-07-25 | Merck Sharp & Dohme LLC | $395 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adju | 2019 |
| 2019-07-24 | Insulet Corporation | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (17 payments) | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2019 | |
| 2019-07-24 | Tandem Diabetes Care, Inc. | $250 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-07-18 | OPKO Pharmaceuticals, LLC | $13,356 | Research payment | Cash or cash equivalent | none Drug | Safety and Efficacy Study of MOD-4023 to Treat Children With Growth Hormone Deficiency | 2019 |
| 2019-07-18 | Merck Sharp & Dohme LLC | $759 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-07-17 | Surmodics, Inc. | $1,545 | Research payment | Cash or cash equivalent | SurVeil Device, Drug-Coated Balloon | TRANSCEND | 2019 |
| 2019-07-17 | Surmodics, Inc. | $1,545 | Research payment | Cash or cash equivalent | SurVeil Device, Drug-Coated Balloon | TRANSCEND | 2019 |
| 2019-07-10 | Merck Sharp & Dohme LLC | $455 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-07-10 | Tandem Diabetes Care, Inc. | $200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-07-10 | Tandem Diabetes Care, Inc. | $200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-07-10 | Merck Sharp & Dohme LLC | $183 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-07-10 | Merck Sharp & Dohme LLC | $158 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-07-10 | Merck Sharp & Dohme LLC | $103 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-07-10 | Merck Sharp & Dohme LLC | $60 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-07-10 | Merck Sharp & Dohme LLC | $3 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-07-10 | Merck Sharp & Dohme LLC | $1 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-07-10 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-07-10 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-07-10 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-07-08 | Osteomed LLC | $5,250 | Grant | Cash or cash equivalent | Device, NEURO-OTHER | 2019 | |
| 2019-07-08 | Osteomed LLC | $5,000 | Grant | Cash or cash equivalent | Device, CMF-OTHER | 2019 | |
| 2019-07-08 | Osteomed LLC | $5,000 | Grant | Cash or cash equivalent | Device, CMF-OTHER | 2019 | |
| 2019-07-03 | Insulet Corporation | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (17 payments) | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2019 | |
| 2019-06-27 | Insulet Corporation | $400 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v (17 payments) | Cash or cash equivalent | Omnipod Device, Insulin Pump | 2019 | |
| 2019-06-26 | Merck Sharp & Dohme LLC | $6,715 | Research payment | Cash or cash equivalent | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-06-26 | Tandem Diabetes Care, Inc. | $200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-06-26 | Tandem Diabetes Care, Inc. | $200 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | t-slim insulin pump Device, Endocrinology | 2019 | |
| 2019-06-25 | Clovis Oncology, Inc. | $100,000 | Grant | Cash or cash equivalent | Rubraca Drug, Oncology | 2019 | |
| 2019-06-25 | Merck Sharp & Dohme LLC | $21,652 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adju | 2019 |
| 2019-06-25 | AstraZeneca Pharmaceuticals LP | $2,946 | Research payment | Cash or cash equivalent | TUDORZA PRESSAIR Drug, Respiratory | Double blind Randomized Placebo controlled Parallel group Study to Evaluate the Effect of Aclidinium Bromide on Long Ter | 2019 |
| 2019-06-25 | Merck Sharp & Dohme LLC | $642 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy ,-Pembrolizumab MK-3475 as Neoadjuvant,Adju | 2019 |
| 2019-06-21 | Agios Pharmaceuticals, Inc. | $10,483 | Research payment | Cash or cash equivalent | A PHASE 1 STUDY OF AG-636 IN THE TREATMENT OF SUBJECTS WITH ADVANCED LYMPHOMA | 2019 | |
| 2019-06-21 | Agios Pharmaceuticals, Inc. | $6,150 | Research payment | Cash or cash equivalent | A PHASE 1 STUDY OF AG-636 IN THE TREATMENT OF SUBJECTS WITH ADVANCED LYMPHOMA | 2019 | |
| 2019-06-21 | Agios Pharmaceuticals, Inc. | $1,890 | Research payment | Cash or cash equivalent | A PHASE 1 STUDY OF AG-636 IN THE TREATMENT OF SUBJECTS WITH ADVANCED LYMPHOMA | 2019 | |
| 2019-06-21 | Agios Pharmaceuticals, Inc. | $1,260 | Research payment | Cash or cash equivalent | A PHASE 1 STUDY OF AG-636 IN THE TREATMENT OF SUBJECTS WITH ADVANCED LYMPHOMA | 2019 | |
| 2019-06-21 | Agios Pharmaceuticals, Inc. | $756 | Research payment | Cash or cash equivalent | A PHASE 1 STUDY OF AG-636 IN THE TREATMENT OF SUBJECTS WITH ADVANCED LYMPHOMA | 2019 | |
| 2019-06-21 | Agios Pharmaceuticals, Inc. | $630 | Research payment | Cash or cash equivalent | A PHASE 1 STUDY OF AG-636 IN THE TREATMENT OF SUBJECTS WITH ADVANCED LYMPHOMA | 2019 | |
| 2019-06-18 | Amgen Inc. | $131,533 | Research payment | Cash or cash equivalent | Kyprolis Biological, Oncology | A Phase I/II Study of the c-Met Inhibitor Cabozantinib as a Targeted Strategy to Reverse Resistance to the Proteasome In | 2019 |
| 2019-06-15 | OXFORD GENE TECHNOLOGY INC | $149 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-06-10 | Merck Sharp & Dohme LLC | $1,076 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-06-10 | Merck Sharp & Dohme LLC | $316 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-06-10 | Merck Sharp & Dohme LLC | $235 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-06-10 | Merck Sharp & Dohme LLC | $235 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-06-10 | Merck Sharp & Dohme LLC | $141 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-06-10 | Merck Sharp & Dohme LLC | $124 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-06-10 | Merck Sharp & Dohme LLC | $94 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-06-10 | Merck Sharp & Dohme LLC | $72 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-06-10 | Merck Sharp & Dohme LLC | $72 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-06-10 | Merck Sharp & Dohme LLC | $59 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-06-10 | Merck Sharp & Dohme LLC | $59 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-06-10 | Merck Sharp & Dohme LLC | $27 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-06-10 | Merck Sharp & Dohme LLC | $14 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-06-10 | Merck Sharp & Dohme LLC | $12 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-06-10 | Merck Sharp & Dohme LLC | $8 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-06-10 | Merck Sharp & Dohme LLC | $7 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-06-10 | Merck Sharp & Dohme LLC | $6 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-06-10 | Merck Sharp & Dohme LLC | $3 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-06-10 | Merck Sharp & Dohme LLC | $3 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
| 2019-06-10 | Merck Sharp & Dohme LLC | $3 | Research payment | In-kind items and services | PREVYMIS Drug, INFECTIOUS DISEASE | A Phase III, Randomized, Double-Blind, Comparator-controlled Study to Evaluate the Efficacy and Safety of MK-8228 Leterm | 2019 |
The latest 200 records of 312.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Omaha, NE, county Douglas County, NE, state Nebraska; placed by its city name.
| Measure | Place (city or town) Omaha, NE | County Douglas County, NE | State Nebraska |
|---|---|---|---|
| Population B01003 | 488,837 | 590,736 | 1,978,707 |
| Population, 2020 census P1 | 486,051 | 584,526 | 1,961,504 |
| Median age B01002 | 35.3 | 35.6 | 37.2 |
| Under 18 B01001 | 24.2% | 25.3% | 24.5% |
| 65 and over B01001 | 14.5% | 14.1% | 16.7% |
| Households B11001 | 201,698 | 238,430 | 797,847 |
| Foreign born B05002 | 11.3% | 10.6% | 8.0% |
| Median household income B19013 | $73,201 | $80,391 | $76,475 |
| Median family income B19113 | $99,432 | $108,805 | $99,751 |
| Per capita income B19301 | $43,638 | $46,334 | $41,751 |
| Poverty rate B17001 | 13.5% | 11.8% | 10.6% |
| Unemployment rate B23025 | 4.2% | 3.8% | 3.0% |
| Civilian labor force B23025 | 264,681 | 320,024 | 1,056,746 |
| Mean commute (minutes) B08013 | 19.6 | 20.0 | 19.2 |
| Bachelor's degree or higher B15003 | 40.1% | 42.1% | 34.6% |
| Housing units B25001 | 213,023 | 251,553 | 863,444 |
| Owner-occupied B25003 | 57.4% | 61.5% | 66.5% |
| Renters B25003 | 42.6% | 38.5% | 33.5% |
| Median home value B25077 | $245,500 | $266,100 | $238,600 |
| Median gross rent B25064 | $1,187 | $1,201 | $1,072 |
| White, not Hispanic B03002 | 63.4% | 65.8% | 75.3% |
| Black B03002 | 11.4% | 10.2% | 4.6% |
| Hispanic or Latino B03002 | 16.2% | 14.5% | 12.7% |
| Asian B03002 | 4.0% | 4.4% | 2.6% |
| American Indian and Alaska Native B03002 | 0.2% | 0.2% | 0.6% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Omaha, NE.
Comments